Table 2 Univariate and multivariate analyses of recurrence-free interval in 69 patients whose NY-ESO-1 antibody responses were evaluated at 12 months.
Univariate analysis HR (95% CI) | P value | Multivariate analysis HR (95% CI) | P value | |
|---|---|---|---|---|
Age (years) (≥70 vs. <70) | 1.08 (0.48–2.44) | 0.85 | ||
Sex (female vs. male) | 0.79 (0.23–2.64) | 0.70 | ||
Tumor location (lower, middle vs. upper) | 0.93 (0.85–1.02) | 0.12 | ||
Histology (differentiated vs. other) | 0.93 (0.39–2.24) | 0.87 | ||
Neoadjuvant chemotherapy (yes vs. no) | 1.48 (0.44–4.97) | 0.52 | ||
Procedure (total vs. partial gastrectomy) | 2.57 (1.12–5.88) | 0.02 | 4.38 (1.77–10.9) | 0.001 |
pT (3, 4 vs. 0, 1, 2) | 1.07 (1.01–1.13) | 0.007 | 1.09 (1.03–1.15) | 0.004 |
pN (2, 3 vs. 0, 1) | 1.15 (1.06–1.25) | <0.001 | 1.08 (0.99–1.17) | 0.09 |
pStage (III, IV vs. 0, I, II) | 1.02 (1.01–1.04) | <0.001 | ||
NY-ESO-1 antibody status at 12 months (positive vs. negative) | 20.6 (4.82–88.0) | <0.001 | 21.6 (4.75–98.7) | <0.001 |
